Bayer Kogenate FS
Bayer HealthCare, Biological Products Division

Contact Search Press Sitemap  
HomePatients & CaregiversHealthcare ProfessionalsPrescribing Information
Prescribing Information
Important Safety Information
Administration
HCP Video
Product Benefits
Hemophilia Awards
EZ-Log
EZ-Log Handheld
EZ-Log Web Client
Clinic Support
Bayer Factor Solutions
Rep Finder
Summer Camps
Patient Education Materials
HCP Resources
HCP FAQ
Bayer Links
Bayer Global
Living with Hemophilia
   General Conditions of Use
Privacy Statement
Imprint
  
 
  

Market Research & Studies

In November of 2003, EZ-Log was tested with a group of patients, parents, nurses, caregivers, and other professionals (such as homecare executives and pharmacy benefits providers) at the 55th Annual Meeting of the National Hemophilia Foundation in Salt Lake City. Here are the results:

  • 93% of survey respondents placed a very high importance on having control over treatment management (i.e. recording treatment and infusion information; obtaining counseling and tips from healthcare providers and nurses).

  • Almost all respondents preferred EZ-Log to an Internet-based service.

  • Over 90% of survey respondents felt their current method of record keeping (including paper diaries, spreadsheets, Advoy, and saving box tops) was inconvenient.


  • Almost all survey respondents were highly impressed with EZ-Log's features and see it as something that will bring about significant improvements in the way they record information.

% Of Respondents Finding EZ-Log Features Valuable
EZ-Log Survey 1

% Of Respondents Saying EZ-Log Offers These Benefits
EZ-Log Survey 2

A few of the responses that were recorded during the anonymous survey:

"We have to have this at our treatment center and everybody in our region needs to see this."

"I've been looking for a new way to record this information. This is a way too cool device. It was about time."

"We've been waiting for something like this."

"This is terrific! It will be a BIG hit!"

"This is an excellent idea. I'll feel a lot better if I can get one of these."

"Great product! Very timely!"


Overview
Security/Privacy
Product Comparison
EZ-Log Sign-in




Bayer Hemophila Awards
Bayer provides grants
to early career investigators, fellows in training, and other allied healthcare professionals.
Learn More


 
  

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.